AbbVie is acquiring Apogee Therapeutics for $10.9B, reinforcing its immunology franchise and address

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis

AbbVie knows how to plan ahead.

ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen co

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhil

US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials

A bipartisan group of United States lawmakers has opened national security investigations into wheth

Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenali

Topline results from Phase 3 EPCORE ® DLBCL-4 trial evaluating epcoritamab in combination with lenal

FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and a

AbbVie wins positive CHMP opinions for Rinvoq in severe alopecia areata and non-segmental vitiligo,

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, ap

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

AbbVie has outperformed the market this year, but its valuation remains modest. The company recently

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segm

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacit

If approved, upadacitinib is expected to be the first systemic medication for patients with non-segm

AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to

Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy&#3

Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (LLY), Johnson and Johns

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quar

AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 bill

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 4.21% on an annualized basis

AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology

Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintain

Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the pri

MAVIRET (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute

SKYRIZI (risankizumab) expands its indication for children and adolescents six years of age and olde

Alphabet sinks 6% on a DeepMind departure as AI names drag the S&P 500 and Nasdaq lower; the Dow

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for

https://www.ft.com/content/cb5e94aa-1687-47fe-b55a-82e273e8b1bd?syn-25a6b1a6=1 

Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the U.S. Food and Drug Administr

AbbVie says nine-year CLL14 data showed longer progression-free survival with venetoclax plus obinut

During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst

On CNBC's Halftime Report, experts picked U.S. 10 Year Treasury, AbbVie, and Devon Energy as top

Joshua Brown is still bullish on Shake Shack, while Malcolm Ethridge recommends Morgan Stanley and J

Coca-Cola is Kevin Simpson's final trade; AbbVie gets upgraded and Sabra Health Care and UnitedH

Bryn Talkington picks AbbVie as final trade with $232 price target. Bill Baruch chooses Entegris . O